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Abstract
Background: Little is currently known regarding sputum smear reversion (acid-fast smear becomes positive again
after negative conversion) during anti-tuberculous treatment. This study aimed to evaluate its occurrence in
patients with pulmonary tuberculosis (TB) and identify factors predicting results of mycobacterial culture for smear-
reversion of sputum samples.
Methods: The retrospective review was performed in a tertiary referral center and a local teaching hospital in
Taiwan. From 2000 to 2007, patients with smear-positive culture-confirmed pulmonary TB experiencing smear
reversion after 14 days of anti-tuberculous treatment were identified.
Results: The 739 patients with smear-positive pulmonary TB had 74 (10%) episodes of sputum smear reversion
that grew Mycobacterium tuberculosis in 22 (30%) (Mtb group). The remaining 52 episodes of culture-negative
sputum samples were classified as the non-Mtb group. The anti-tuberculous regimen was modified after
confirming smear reversion in 15 (20%). Fourteen episodes in the Mtb group and 15 in the non-Mtb group
occurred during hospitalization. All were admitted to the negative-pressure rooms at the time of smear reversion.
Statistical analysis showed that any TB drug resistance, smear reversion within the first two months of treatment or
before culture conversion, and the absence of radiographic improvement before smear reversion were associated
with the Mtb group. None of the smear reversion was due to viable M. tuberculosis if none of the four factors were
present.
Conclusions: Sputum smear reversion develops in 10% of patients with smear-positive pulmonary TB, with 30%
due to viable M. tuberculosis bacilli. Isolation and regimen modification may not be necessary for all drug-
susceptible patients who already have radiographic improvement and develop smear reversion after two months
of treatment or after sputum culture conversion.
Background
Tuberculosis (TB) remains a global health problem
despite near eradication in some developed countries
[1-4]. In 2005, the incidence was 76 per 100,000 popula-
tion in Taiwan, 80 per 100,000 in the Republic of Korea,
and 600 per 100000 in South Africa [1,2]. To prevent
further dissemination of Mycobacterium tuberculosis
from TB patients, adequate anti-tuberculous treatment
with the implementation of the Directly Observed Ther-
apy (DOT) is important [5]. This is meant to achieve
negative conversion of sputum smear for acid-fast bacilli
(AFB) and culture for M. tuberculosis.
In some TB patients, follow-up sputum smears occa-
sionally reveal AFB after negative conversion (smear rever-
sion). To avoid transmission, those with sputum smear
reversion are usually admitted in a negative-pressure isola-
tion room if hospitalization is indicated. The anti-tubercu-
lous regimen is modified under the impression of
treatment failure, drug resistance, or poor adherence.
Indeed, only those with viable M. tuberculosis bacilli
should receive proper isolation and further work-up.
However, mycobacterial culture results are available only
after 1-2 weeks using fluorometric culture technique, and
4-6 weeks by conventional solid culture medium [6]. The
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good sensitivity and specificity, are expensive and do not
discriminate between viable and dead bacilli [7].
Therefore, from a practical standpoint, it is very
important to understand how to differentiate among
viable M. tuberculosis, dead bacilli, and non-tuberculous
mycobacteria (NTM) in order to identify cases that
remain infectious and reduce unnecessary expenditure
of medical resources. This issue is not properly
addressed in current literature. This retrospective study
aimed to identify TB patients with smear reversion dur-
ing anti-tuberculous treatment and to compare the clini-
cal characteristics between those whose sputum samples
remained culture-positive for M. tuberculosis and those
whose sputum samples were culture-negative. The study
also tried to identify factors predicting the results of
mycobacterial culture upon sputum smear reversion
after anti-tuberculosis treatment.
Methods
Study subjects
This study was conducted in a 2000-bed tertiary-care
referral center in northern Taiwan and its branch, a
500-bed local teaching hospital in southern Taiwan. The
Institutional Review Board of the hospital’s Research
Ethics Committee approved the protocol. By review of
the database of mycobacterial laboratories, all patients
with smear-positive, culture-confirmed pulmonary TB
from 2000 to 2007 in the tertiary-care referral center
and from 2004 to 2007 in the local teaching hospital
were identified.
Patients whose sputum samples became smear-posi-
tive for AFB after having three consecutive smear-nega-
tive sputum samples and having received anti-
tuberculous treatment for more than 14 days (sputum
smear reversion) were identified. They were classified
into the M. tuberculosis group (Mtb group) if their spu-
tum samples at smear reversion were culture-positive
for M. tuberculosis, and the non-Mtb group if their spu-
tum samples at smear reversion were culture-negative.
Mycobacterial study
Sputum samples were processed and pre-treated as pre-
viously described [8]. AFB smears of the processed sam-
ples were stained by the Kinyoun method and examined
using standard procedures [9]. Smear grading was noted
according to the American Thoracic Society guidelines
[10]. If several sputum samples collected in the same per-
iod from a patient were smear-positive but with different
grades, the highest was recorded as the patient’s smear
grading. From November 2006, the auramine-rhodamine
fluorochrome method was used for screening before the
smear was confirmed by the Kinyoun method [9].
The medium for primary mycobacterial isolation was
Middlebrook 7H11 selective agar with antimicrobials
(Remel Inc., Lexena, Kans.) and the fluorometric BAC-
TEC technique (BACTEC Mycobacterium Growth Indi-
cator Tube [MGIT] 960 system, Becton-Dickinson).
Mycobacterial species were identified using conventional
biochemical testing [9]. The susceptibility test of first-
line anti-tuberculous drugs was examined using two
concentrations of isoniazid (0.2 and 1.0 μg/ml) and
ethambutol (7.5 and 15 μg/ml), and one concentration
of rifampicin (1.0 μg / m l )[ 1 1 ] .F o ri s o n i a z i da n de t h a m -
butol, low-level resistance was defined as resistance.
Terminology definition and data collection
The patients’ medical charts and interview records from
TB case managers were reviewed to collect clinical data,
including age, gender, underlying co-morbidity, symp-
toms, and results of laboratory tests and radiographic
findings upon initial diagnosis and on sputum smear
reversion. Management with smear reversion and out-
come at the end of follow-up were also recorded.
In the two hospitals, patients with smear-positive pul-
monary TB were requested to submit three sputum
samples for acid-fast smear and mycobacterial culture
every two weeks until smear conversion, and then
monthly until culture conversion. Sputum culture con-
version after anti-tuberculous treatment was achieved if
three consecutive sputum samples were culture-negative
for M. tuberculosis. The sputum mycobacterial load dur-
ing smear reversion was considered “high” if there were
multiple 3+ or 4+ positive smears, “medium” if there
were multiple 2+ positive smears, and “low” for the rest.
A single pulmonologist and a single radiologist both
blinded to the clinical data interpreted the findings on
chest radiography. If their opinions differed, the films
were reviewed by another senior pulmonologist blinded
to the results. Radiographically, “no improvement” was
considered if the lesions seen on smear reversion did
not decrease in size as compared to those before anti-
tuberculous treatment, or if there were new lesions.
Standard anti-tuberculous treatment was defined as
daily isoniazid, rifampicin, ethambutol, and pyrazina-
mide (HREZ) for the first 2 months (intensive phase),
followed by daily isoniazid and rifampicin for 4 months
(continuation phase) [12]. Primary-care physicians modi-
fied the regimen based on any concomitant hepatic/
renal disease, adverse events, or results of susceptibility
testing. The government began the Directly Observed
Therapy-short course (DOTs), which covered the entire
course of anti-tuberculous treatment, in April 2006.
Treatment failure was defined as the presence of cultur-
able M. tuberculosis in sputum samples after 4 months
of anti-tuberculous treatment [13].
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Inter-group differences were compared using the chi-
square test or Fisher exact test for categorical variables,
if appropriate. Time to smear reversion and survival
were compared by the Kaplan-Meier method using the
log-rank test. Variables with a significant difference (p <
0.05) in univariate analysis were further tested by multi-
variate logistic regression analysis to identify indepen-
dent factors predictive of the results of mycobacterial
culture on sputum smear reversion.
Results
Seven hundred and thirty-nine (739) patients with
smear-positive culture-confirmed pulmonary TB were
identified. The pre-treatment M. tuberculosis isolate
was multi-drug resistant (MDR) in 49, resistant but
not MDR in 114, and all susceptible in the remaining
576. There were 68 patients with 74 (10.0%) episodes
of sputum smear reversion, one with three episodes,
and another four with two episodes. Mycobacterial cul-
ture of sputum samples on smear reversion yielded M.
tuberculosis in 22 episodes, NTM in 5, and negative in
the remaining 47. The former 22 (30%) was defined as
the Mtb group and the rest as the non-Mtb group.
The median number of sputum samples collected
upon smear reversion was 3 (range: 2-6 sets). Of the
46 episodes of smear reversion that developed after
November 2006, nine (20%) were due to viable M.
tuberculosis bacilli. In the Mtb group, the pre-treat-
ment M. tuberculosis isolate was MDR in five (10% of
the 49 patients with MDR TB) and was resistant but
not MDR in six (5.3% of the 114 patients with resistant
but not MDR TB).
The clinical characteristics of the two groups were
similar but more patients in the Mtb group had smear
reversion within the first two months of anti-tubercu-
lous treatment and before sputum culture conversion.
More patients in the Mtb group also had no improve-
ment in symptoms before smear reversion and were not
treated under DOTs (Table 1). Four in the Mtb group
developed smear reversion after nine months of anti-
tuberculous treatment. About half of the patients in
each group had underlying diseases, which were most
commonly diabetes mellitus and malignancy (Additional
file 1: Table S1). Two patients in the non-Mtb group
were co-infected by the human immunodeficiency virus
(HIV). The Mtb group had a higher rate of resistance
against tested first-line drugs and higher mycobacterial
load (medium to high) on smear reversion (Table 2). A
significantly higher proportion of patients in the Mtb
group had no radiographic improvement before smear
reversion than those in the non-Mtb group (p = 0.005).
Both groups were divided into two sub-groups each
based on the susceptibility results of the pre-treatment
M. tuberculosis isolates, and were compared (Additional
file 1: Tables S1 and S2). The findings were similar
except for: 1) the proportions of patients treated under
DOTs were not significantly different (p = 0.073); 2) the
proportions of patients whose anti-tuberculous regimen
had ever been modified were significantly different (p <
0.001); and 3) the time to smear reversion was signifi-
cantly different (Figure 1).
The anti-tuberculous regimen was modified in
15 (20%) episodes after knowing smear reversion. In the
29 episodes that occurred during hospitalization, includ-
ing 14 (64%) in the Mtb group and 15 (29%) in the
Table 1 Clinical characteristics of patients with smear reversion
Mtb group
(n = 22)
Non-Mtb group
(n = 52)
p value
Age ≥ 65 years 9 (41%) 24 (46%) 0.678
Male gender 16 (73%) 43 (83%) 0.330
*Underlying co-morbid condition 10 (48%) 30 (57%) 0.334
Timing of smear reversion after treatment
Median (range): days 68 (16 ~ 647) 135 (43 ~ 760) 0.240
†
Within 2 months 9 (41%) 5 (10%) 0.002
Before sputum culture conversion 17 (77%) 11 (20%) < 0.001
*Symptoms not improved at smear reversion 13 (59%) 15 (29%) 0.014
Regimen modification before smear reversion 13 (59%) 19 (37%) 0.073
Receiving direct observed therapy 9 (41%) 41 (79%) 0.002
Mortality at the end of follow-up 7 (32%) 8 (15%) 0.118
Median survival: months 12.8 11.1 0.178
†
Treatment failure 6 (27%) 5 (10%) 0.051
Data are no. (%), unless otherwise indicated.
*The detail of underlying co-morbid condition and symptoms were described in additional file 1: Table S1.
†p value was calculated by the Kaplan-Meier method.
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room on smear reversion. The survival and outcome
were similar in the two groups, though the Mtb group
had a slightly, but insignificantly, higher rate of treat-
ment failure than the non-Mtb group (p = 0.051, Table
1).
Of the 22 episodes of M. tuberculosis-associated smear
reversion (Additional file 1: Table S3 and S4), the anti-
tuberculous regimen was modified or interrupted before
smear reversion in 13 (59%). The most common causes
were adverse events (seven episodes) and resistance of
pre-treatment M. tuberculosis isolates (seven episodes).
Anti-tuberculous treatment was interrupted due to ileus
in one patient and poor adherence in another. In the
nine episodes without treatment modification before
smear reversion, four had underlying diseases while the
other five occurred within the first two months of treat-
ment. None of the patients with M. tuberculosis-asso-
ciated smear reversion that occurred within two months
of anti-tuberculous treatment had treatment failure.
Of the 22 clinical isolates of M. tuberculosis during
smear reversion, drug susceptibility testing was repeated
for 14, which revealed additional drug resistance in two
isolates. Two isolates on smear reversion were multi-
drug resistant strains. The pre-treatment isolates of the
two patients were all-susceptible in one and rifampicin-
resistant in the other.
Seven variables were included in the multivariate
logistic regression analysis: treatment under DOTs strat-
egy, presence of any TB drug resistance of the pre-treat-
ment M. tuberculosis isolate, timing of smear reversion
after treatment, smear reversion before sputum culture
conversion, sputum mycobacterial load at reversion, and
improvement of symptoms and radiographic findings
before smear reversion (Additional file 2: Table S1). The
results showed that factors independently predicting the
results of mycobacterial culture on smear reversion were
any TB drug resistance (OR: 10.33; 95% C.I.:1.47-72.60),
sputum smear reversion within 2 months after
anti-tuberculous treatment (OR: 16.31; 95% C.I.:
2.02-131.64), smear reversion before sputum culture
conversion (OR: 29.55; 95% C.I.: 4.07-214.72), and no
radiographic improvement before smear reversion
(OR: 23.57; 95% C.I.: 2.49-223.38) (Table 3).
In order to evaluate the impact of treatment under
DOTS, this variable was forcedly included in the final
model of the multivariate analysis. The results showed
that DOTS was not an independent predictor of culture
results (p = 0.435) and the ORs for the four other vari-
ables did not significantly change.
The predictive values of the four associated factors were
calculated (Table 4). If three or more factors existed, the
Table 2 Laboratory and radiographic findings in patients
with smear reversion
Mtb
group
(n = 22)
Non-Mtb
group
(n = 52)
p
value
Mycobacterial load at
smear reversion
0.007
High 3 (14%) 1 (2%)
Medium 8 (36%) 9 (17%)
*Resistance of pre-treatment
Mtb isolate
Any TB drug resistance 11 (50%) 9 (17%) 0.004
Multidrug resistance 5 (23%) 1 (2%) 0.009
Finding of chest film
Bilateral involvement at initial 16 (73%) 33 (63%) 0.441
Cavitary lesion at initial 7 (32%) 12 (23%) 0.431
Not improved at smear
reversion
19 (86%) 27 (52%) 0.005
Blood tests at reversion
Leukocyte
(>11000 or <4000/μL)
6 (27%) 11 (21%) 0.555
Hemoglobin (< 12 g/dL) 13 (63%) 19 (42%) 0.055
Albumin (< 3.5 g/dL) 4 (36%) 7 (50%) 0.495
Total Bilirubin (> 1.2 mg/dL) 2 (11%) 6 (16%) 0.614
Creatinine (> 1.5 mg/dL) 3 (17%) 4 (9%) 0.358
Abbreviation: Mtb, Mycobacterium tuberculosis; TB, tuberculosis
Data are no. (%) or mean [no. of tested patients], unless otherwise indicated.
*The details of resistance of pre-treatment isolate were described in additional
file 1: Table S2.
Figure 1 Each of the Mycobacterium tuberculosis (Mtb) and
non-Mtb groups was divided into two sub-groups based on
susceptibility results of the pre-treatment M. tuberculosis
isolates. Time to smear reversion was plotted by the Kaplan Meier
method and compared using log-rank test.
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present, the negative predictive value was 100%. The posi-
tive and negative predictive values when any two factors
were considered were 64% and 98%, respectively.
Discussion
Sputum smear reversion after smear negative conversion
during anti-tuberculous therapy is usually considered a
sign of sub-optimal treatment or poor adherence [14,15].
Aside from evaluating and fostering patient compliance,
new drugs are frequently added under the suspicion of
emerging drug resistance. In addition, isolation in a
negative-pressure room is deemed necessary if sputum
smear reversion occurs during hospitalization. The
results of this study suggest that sputum smear reversion
develops in about 10% of patients with smear-positive,
culture-confirmed pulmonary TB in an endemic area. Of
these, 30% is caused by viable M. tuberculosis,w h i c h
imply that altering treatment plans or doing contact
isolation may not be necessary in the majority of those
with sputum smear reversion. Therefore, understanding
the factors predictive of results of mycobacterial culture
upon sputum smear reversion is extremely important to
reduce unnecessary medical cost.
In this study, factors independently associated with the
presence of viable M. tuberculosis on sputum smear
reversion include smear reversion within the first two
months of anti-tuberculous treatment and before spu-
tum culture conversion, the presence of drug resistance,
and the absence of radiographic improvement before
smear reversion. The results show that the presence of
viable M. tuberculosis bacilli is less likely if none or one
of the four factors is present. Hence, medical resources
can be saved by applying the four factors to predict the
results of mycobacterial culture.
The statistical analysis reveals that the absence of any
radiographic improvement before sputum smear conver-
sion is the strongest predictor for the results of myco-
bacterial culture. Although chest radiography is usually
feasible and results can be available within the same
day, the interpretation can sometimes be confounded
during anti-tuberculous treatment. NTM pulmonary
infection or colonization can result in higher smear
grading and possibly, radiographic progression indistin-
guishable from pulmonary TB [16-18]. In addition,
concomitant pulmonary malignancy or chronic lung
disease, or paradoxical deterioration under successful
treatment, renders the interpretation more difficult [19].
These factors also seriously compromise accuracy in
evaluating subjective symptoms [18,20]. Nonetheless, the
findings here suggest that careful interpretation and dif-
ferentiation of etiologies responsible for the radiographic
changes are important in managing TB patients with
smear reversion.
Patients who develop M. tuberculosis-associated spu-
tum smear reversion have higher any TB drug resistance
rate (50%) than those whose sputum samples are culture-
negative for M. tuberculosis on smear reversion (17%)
and in the general TB population (17.7-20.4%) [11,21].
Current evidence suggests that in areas with low preva-
lence of drug resistance, prescription modification is not
necessary even if the pre-treatment isolate is mono-drug
Table 3 Factors associated with the presence of viable M. tuberculosis bacilli on sputum smear reversion in
multivariate analysis
Characteristics Episodes no. Cul (+) for Mtb OR (95% CI.)
Any TB drug resistance Yes 20 11 (55%) 10.33 (1.47-72.60)
No 54 11 (20%)
Mycobacterial load at reversion Medium or high 21 11 (52%) 16.74 (0.95-296.48)
Low 53 11 (21%)
Timing of Sm reversion after treatment ≤ 2 months 14 9 (64%) 16.31 (2.02-131.64)
> 2 months 60 13 (22%)
Sm reversion before Cul conversion Yes 28 17 (61%) 29.55 (4.07-214.72)
No 46 5 (11%)
Findings of chest film at Sm reversion Not improved 46 19 (41%) 23.57 (2.49-223.38)
Improved 28 3 (11%)
Abbreviation: Cul, culture; Mtb, Mycobacterium tuberculosis; Sm, smear; TB, tuberculosis
The details of multivariate analysis were listed in Additional file 2: Table S1.
Table 4 Predicting the result of mycobacterial culture on
smear reversion by four clinical factors
Conditions Episodes of Sm
reversion
Cul (+)
for Mtb
Se Sp PPV NPV
All 1 1 5% 100% 100% 72%
Any three 1 1 5% 100% 100% 72%
Any two 33 21 95% 78% 64% 98%
Anyone 61 22 100% 28% 36% 100%
Abbreviation: Cul, culture; Mtb, Mycobacterium tuberculosis; NPV, negative
predictive value; PPV, positive predictive value; Se, sensitivity; Sm, smear; Sp,
specificity
The four clinical factors include: 1) any one-drug resistance; 2) smear reversion
within 2 months after treatment; 3) smear reversion before culture conversion;
and 4) no radiographic improvement before smear reversion
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month of standard treatment [22]. However, patients in
the Mtb group with drug resistance had smear reversal
more than 2 months so that periodic sputum examina-
tions and imaging studies in patients with drug-resistant
TB may be needed for the early detection of emerging
resistance and possible treatment failure.
This study reveals that the timing of sputum smear
reversion is also an important predictor for the presence
of viable M. tuberculosis bacilli. The underlying patho-
physiology is most likely the rapidly decreased viability
under effective combined anti-tuberculous chemother-
apy. A sub-optimal, or even failed, regimen is not an
important practical concern because none of those with
sputum smear reversion within two months of anti-
tuberculous treatment has treatment failure. Consistent
with previous studies, only smear positivity after two
months of anti-tuberculous treatment is associated with
poor treatment outcome [23,24].
Because sputum production is an irregular process,
M. tuberculosis bacilli are potentially expectorated inter-
mittently. Quantification of mycobacterial load at
sputum reversion is determined by smear grading and
reproducibility. However, a medium-to-high mycobac-
terial load on reversion reveals an insignificant associa-
tion with the Mtb group by multivariate analysis. This is
p r o b a b l yd u et ot h ep r e s e n c eo fd e a dM. tuberculosis
bacilli after anti-tuberculosis treatment. Another possi-
b l ee x p l a n a t i o nm a yb et h es m a l ls a m p l es i z eo ft h e
study, which limits the statistical power to detect
true differences between the two groups. Underlying
co-morbidity, even HIV infection, is not associated with
culture-positive smear reversion under standard anti-
tuberculous treatment. As shown in previous studies,
HIV infection is not associated with significantly longer
smear conversion time and worse prognosis [25,26].
This study has several limitations. First, although TB
treatment guidelines are well established and implemen-
ted in clinical practice, the anti-tuberculous regimens
and re-challenge protocols used in this study are hetero-
geneous due to the retrospective design. Second, the
prevalence of smear reversion is likely to be underesti-
mated because not all TB patients treated in the hospital
during the study period regularly underwent sputum
examinations. Third, due to the small sample size, con-
clusive generalizations cannot be made and other inde-
pendent predictors, like drug adherence, for the
presence of viable M. tuberculosis bacilli may not be sta-
tistically significant. Prospective, large-scale studies are
warranted.
Conclusions
Sputum smear reversion develops in 10% of patients
with smear-positive, culture-confirmed pulmonary TB in
an endemic area. Of these, about 30% are due to viable
M. tuberculosis bacilli. Proper contact isolation and
investigation of possible sub-optimal treatment should
be prioritised in those with drug-resistant TB, those
who develop smear reversion within two months after
anti-tuberculous treatment or before sputum culture
conversion, or those without radiographic improvement
before smear reversion.
Additional file 1: Clinical characteristics, laboratory and
radiographic findings in patients with smear reversion. Clinical
characteristics, laboratory and radiographic findings of the patients with
smear reversion were described, listed and compared according to the
susceptibility of the patients’ pre-treatment isolates.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2334-10-
48-S1.DOC]
Additional file 2: Factors associated with the presence of viable M.
tuberculosis bacilli on sputum smear reversion. A table of multivariate
analysis showed the details of the association between presence of
viable M. tuberculosis bacilli on sputum smear reversion and seven
significant factors from the univariate analysis.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2334-10-
48-S2.DOC]
Acknowledgements
We thank the members of the Taiwan Anti-Mycobacteria Investigation
(TAMI) group for data collection and analysis. The members of the group
include Jann-Yuan Wang; Li-Na Lee; Chong-Jen Yu; Pan-Chyr Yang; Hsin-Chih
Lai; Wei-Juin Su; Chin-Chung Shu; Chih-Hsin Lee and Ming-Chih Yu.
Funding source: This study was supported by the Institute for
Biotechnology and Medicine Industry, Taiwan.
Author details
1Department of Traumatology, National Taiwan University Hospital, Taipei,
Taiwan.
2Department of Internal Medicine, National Taiwan University
Hospital, Taipei, Taiwan.
3Department of Internal Medicine, Buddhist Tzu Chi
General Hospital, Taipei Branch, Taipei, Taiwan.
4Department of Laboratory
Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Authors’ contributions
JY, LN, and CJ participated in designing the study. CC participated in
collecting all relevant data and wrote the manuscript. JT, CH, LN and CJ
were performed the data analysis. PC and JY conceived of the study, and
participated in its coordination. All authors read and approved the final
manuscript.
Competing interests
All of the authors declare no financial, professional, or otherwise personal
interest of any nature or kind in related product, service, and/or company.
Received: 19 August 2009 Accepted: 6 March 2010
Published: 6 March 2010
References
1. Kuo SHS, Yi SW, Ting L, et al: Taiwan Tuberculosis Control Report 2007.
Taipei: Centers for Disease Control, Department of Health, R.O.C (Taiwan),
4 2008.
2. Harling G, Ehrlich R, Myer L: The social epidemiology of tuberculosis in
South Africa: a multi-level analysis. Soc Sci Med 2008, 66(2):492-505.
3. Shimouchi A: Tuberculosis problems in the Asia-Pacific region. Respirology
2001, 6(1):75-78.
4. Centers for Disease Control and Prevention (CDC): Trends in tuberculosis–
United States, 2008. MMWR Morb Mortal Wkly Rep 2009, 58(10):249-253.
Shu et al. BMC Infectious Diseases 2010, 10:48
http://www.biomedcentral.com/1471-2334/10/48
Page 6 of 75. Albert RK, Iseman M, Sbarbaro JA, Stage A, Pierson DJ: Monitoring patients
with tuberculosis for failure during and after treatment. Am Rev Respir Dis
1976, 114(6):1051-1060.
6. Lu D, Heeren B, Dunne WM: Comparison of the Automated Mycobacteria
Growth Indicator Tube System (BACTEC 960/MGIT) with Lowenstein-
Jensen medium for recovery of mycobacteria from clinical specimens.
Am J Clin Pathol 2002, 118(4):542-545.
7. Wang JY, Lee LN, Hsu HL, Hsueh PR, Luh KT: Performance assessment of
the DR. MTBC Screen assay and the BD ProbeTec ET system for direct
detection of Mycobacterium tuberculosis in respiratory specimens. J Clin
Microbiol 2006, 44(3):716-719.
8. Wang JY, Lee LN, Chou CS, et al: Performance Assessment of a Nested-
PCR Assay (the RAPID BAP-MTB) and the BD ProbeTec ET System for
Detection of Mycobacterium tuberculosis in Clinical Specimens. J Clin
Microbiol 2004, 42(10):4599-4603.
9. Pfyffer VV, Christina Gutiérrez M, Brown-Elliott BA, Wallace RJ:
Myobacterium. Manual of Clinical Microbiology Washington, DC: American
Society for MicrobiologyPatrick R, Murray EJB, JH Jorgensen, MA Pfaller,
Marie L Landry , 6 2007.
10. American Thoracic Society Centers for Disease Control and Prevention:
Diagnostic Standards and Classification of Tuberculosis in Adults and
Children. Am J Respir Crit Care Med 2000, 161(4 Pt 1):1376-1395.
11. Yu MC, Wu MH, Jou R: Extensively drug-resistant tuberculosis, Taiwan.
Emerg Infect Dis 2008, 14(5):849-850.
12. Centers for Disease Control and Prevention (CDC): Treatment of
tuberculosis. MMWR Recomm Rep 2003, 52(RR-11):1-77.
13. Luh KT, (ed): Taiwan guidelines for TB diangosis and treatment. Taipei:
Center for Disease Control, Executive Yuan, Taiwan (R.O.C.), 3 2008.
14. Zhao FZ, Levy MH, Wen S: Sputum microscopy results at two and three
months predict outcome of tuberculosis treatment. Int J Tuberc Lung Dis
1997, 1(6):570-572.
15. Salaniponi FM, Christensen JJ, Gausi F, Kwanjana JJ, Harries AD: Sputum
smear status at two months and subsequent treatment outcome in new
patients with smear-positive pulmonary tuberculosis. Int J Tuberc Lung
Dis 1999, 3(11):1047-1048.
16. Huang CT, Tsai YJ, Shu CC, et al: Clinical significance of isolation of
nontuberculous mycobacteria in pulmonary tuberculosis patients. Respir
Med 2009 2009, 103(10):1484-91.
17. Griffith DE, Aksamit T, Brown-Elliott BA, et al: An official ATS/IDSA
statement: diagnosis, treatment, and prevention of nontuberculous
mycobacterial diseases. Am J Respir Crit Care Med 2007, 175(4):367-416.
18. Koh WJ, Yu CM, Suh GY, et al: Pulmonary TB and NTM lung disease:
comparison of characteristics in patients with AFB smear-positive
sputum. Int J Tuberc Lung Dis 2006, 10(9):1001-1007.
19. Wendel KA, Alwood KS, Gachuhi R, et al: Paradoxical worsening of
tuberculosis in HIV-infected persons. Chest 2001, 120(1):193-197.
20. Shu CC, Lee CH, Wang JY, et al: Non-tuberculous mycobacteria
pulmonary infection in medical intensive care unit: the incidence,
patient characteristics, and clinical significance. Intensive Care Med 2008,
34(12):2194-2201.
21. Lai CC, Tan CK, Huang YT, et al: Extensively drug-resistant Mycobacterium
tuberculosis during a trend of decreasing drug resistance from 2000
through 2006 at a Medical Center in Taiwan. Clin Infect Dis 2008, 47(7):
e57-63.
22. Kim SJ: Drug-susceptibility testing in tuberculosis: methods and
reliability of results. Eur Respir J 2005, 25(3):564-569.
23. Rieder HL: Sputum smear conversion during directly observed treatment
for tuberculosis. Tuber Lung Dis 1996, 77(2):124-129.
24. Lienhardt C, Manneh K, Bouchier V, et al: Factors determining the
outcome of treatment of adult smear-positive tuberculosis cases in The
Gambia. Int J Tuberc Lung Dis 1998, 2(9):712-718.
25. Wang JY, Hsueh PR, Wang SK, et al: Disseminated tuberculosis: a 10-year
experience in a medical center. Medicine 2007, 86(1):39-46.
26. Wang JY, Lee LN, Yu CJ, Chien YJ, Yang PC: Factors influencing time to
smear conversion in patients with smear-positive pulmonary
tuberculosis. Respirology 2009, 14(7):1012-1019.
Pre-publication history
The pre-publication history for this paper can be accessed here:
[http://www.biomedcentral.com/1471-2334/10/48/prepub]
doi:10.1186/1471-2334-10-48
Cite this article as: Shu et al.: Predicting results of mycobacterial culture
on sputum smear reversion after anti-tuberculous treatment: a case
control study. BMC Infectious Diseases 2010 10:48.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Shu et al. BMC Infectious Diseases 2010, 10:48
http://www.biomedcentral.com/1471-2334/10/48
Page 7 of 7